Evidence map›Paper›PMID 27444792›Full record

ArticleMolecular genetics and metabolism2016

Mitochondrial disease patients' perception of dietary supplements' use.

Amel Karaa, Joshua Kriger, Johnston Grier, Amy Holbert, John L P Thompson, Sumit Parikh, Michio Hirano

Abstract read
In one paragraph

Article in Molecular genetics and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. The North American mitochondrial disease registry.Journal of translational genetics and genomics · 2020
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Amel KaraaThe Genetics Unit at the Massachusetts General Hospital, Harvard University, Boston, MA 02114, United States. Electronic address: akaraa@mgh.harvard.edu.
Joshua KrigerDepartment of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY 10032, United States. Electronic address: jk3563@cumc.columbia.edu.
Johnston GrierDepartment of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY 10032, United States. Electronic address: jg3145@cumc.columbia.edu.
Amy HolbertHealth Informatics Institute, University of South Florida, Tampa, FL, United States. Electronic address: amy.holbert@epi.usf.edu.
John L P ThompsonDepartment of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY 10032, United States. Electronic address: jlt12@cumc.columbia.edu.
Sumit ParikhDepartment of Neurology, Cleveland Clinic, Cleveland, OH, United States. Electronic address: parikhs@ccf.org.
Michio HiranoDepartment of Neurology, Columbia University Medical Center, New York, NY 10032, United States. Electronic address: mh29@cumc.columbia.edu.
Columbia University Irving Medical Center · USCleveland Clinic · USHarvard University · USUniversity of South Florida · US

Funding

The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRANO, MICHIO · 2011 to 2023
$17.5M
NINDS NIH HHS U54 NS078059
6 · The paper itself

Abstract

Surveys of mitochondrial disease physicians conducted through the Mitochondrial Medicine Society have shown that virtually all providers recommend a variety of dietary supplements as treatments to their patients in an effort to enhance energy production and reduce oxidative stress. In this survey, we asked patients and their parents about their experiences taking these dietary supplements for mitochondrial disease. The survey was disseminated through the North American Mitochondrial Disease Consortium (NAMDC) and the Rare Disease Clinical Research Network (RDCRN) registries and gathered 162 responses. The study ascertained each patient's mitochondrial disease diagnosis, dietary supplements used, adjunct therapy, and effects of the supplements on symptoms and health. Regardless of the specific underlying mitochondrial disease, the majority of the survey respondents stated they are or have been on dietary supplements. Most patients take more than four supplements primarily coenzyme Q10, l-carnitine, and riboflavin. The majority of patients taking supplements reported health benefits from the supplements. The onset of perceived benefits was between 2weeks to 3months of initiating intake. Supplements seem to be safe, with only 28% of patients experiencing mild side-effects and only 5.6% discontinuing their intake due to intolerance. Only 9% of patients had insurance coverage for their supplements and when paying out of pocket, 95% of them spend up to $500/month. Despite the use of concomitant therapies (prescribed medications, physical therapy, diet changes and other), 45.5% of patients think that dietary supplements are the only intervention improving their symptoms. Some limitations of this study include the retrospective collection of data probably associated with substantial recall bias, lack of longitudinal follow up to document pre- and post-supplement clinical status and second hand reports by parents for children which may reflect parents' subjective interpretation of symptoms severity and supplements effect rather than real patients' experience. More extensive prospective studies will help further elucidate this topic.

Indexed as

CarnitineChildDietary SupplementsDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMitochondrial DiseasesOxidative StressParentsPatientsSurveys and QuestionnairesUbiquinoneCarnitinecoenzyme Q10UbiquinoneDietary supplementsMitochondrial diseaseSurvey

Identifiers

PMID27444792
PMCPMC5031526
OpenAlexW2216423421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.